The association between daily physical activity and plasma B-type natriuretic peptide in patients with glucose intolerance: a cross-sectional study

Hidetaka Hamasaki,1,2 Hidekatsu Yanai,1 Masafumi Kakei,2 Mitsuhiko Noda,3 Osamu Ezaki4

ABSTRACT

Objectives: In spite of accumulating evidences suggesting an inverse association between insulin resistance and plasma B-type natriuretic peptide (BNP) levels, the effect of daily physical activity on plasma BNP in individuals with glucose intolerance remains unknown. We investigated the association of physical activity level (PAL) with plasma BNP in patients with impaired fasting glucose, impaired glucose tolerance and type 2 diabetes.

Design: Cross-sectional study.

Setting: Outpatients visiting the National Center for Global Health and Medicine Kohnodai Hospital.

Participants: A total of 60 patients with glucose intolerance who did not take any hypoglycaemic agents, cholesterol-lowering agents and antihypertensive agents were recruited. Patients who were diagnosed as having heart failure and renal impairment, engaged in sports-like exercise and resistance training were excluded.

Primary outcome measures: PAL was objectively measured by a triaxial accelerometer. The association between PAL and plasma BNP levels was assessed by multiple regression analysis.

Results: PAL was positively correlated with plasma BNP levels (r=0.296, p=0.021). PAL was still significantly correlated with plasma BNP levels after adjustment for age (β=0.290, p=0.014), and adjustment for age and body mass index (β=0.282, p=0.018). Plasma BNP levels were inversely correlated with serum insulin levels (r=−0.350, p=0.006) and homeostasis model assessment-estimated insulin resistance (HOMA-IR; r=−0.363, p=0.004). Serum insulin levels (mean±SD, 8.1±6.4 μU/mL) and HOMA-IR (2.4±1.9) in the high-BNP group were significantly lower than those (11.2±7.4 μU/mL and 3.7±3.0, respectively) in the low-BNP group.

Conclusions: Our findings propose the possibility that plasma BNP may be increased by daily physical activity and BNP is associated with insulin resistance.

INTRODUCTION

B-type natriuretic peptide (BNP) belongs to the cardiac natriuretic peptide family which are released from the heart in response to pressure and volume overload.1 Plasma BNP and N-terminal proBNP (Nt-proBNP) are increased with the severity of left ventricular dysfunction and/or hypertrophy; therefore, it has become a useful biomarker for the diagnosis and prognosis of heart failure with or without type 2 diabetes.8–7

Plasma BNP levels have been reported to be inversely related to the body mass index (BMI) and waist circumference in individuals without heart failure.8–9 Very recently, Olsen et al10 reported that Nt-proBNP was significantly lower in individuals with the metabolic syndrome as compared with those without the metabolic syndrome. In their study, the Nt-proBNP levels were inversely correlated with BMI, waist circumference, serum
cholesterol and triglyceride, plasma glucose and insulin, independently of age and gender. These results suggest that BNP is beneficially associated with obesity and obesity-related metabolic disorders. Low physical activity and a sedentary lifestyle induce the development of type 2 diabetes, and also deteriorate glucose control in patients with type 2 diabetes. Exercise such as bicycle and hand-grip exercise has been reported to acutely increase plasma BNP levels with exercise intensity, in healthy individuals. However, the effect of daily physical activity on plasma BNP levels remains obscure. To the best of our knowledge, there were no previous studies that investigated the association between daily physical activity and plasma BNP levels in patients with glucose intolerance. We studied the association of physical activity level (PAL), which was evaluated objectively by using a triaxial accelerometer, with plasma BNP levels, in patients with impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and type 2 diabetes. Furthermore, we elucidated the correlations of plasma BNP levels with metabolic parameters in patients with such glucose intolerance.

MATERIAL AND METHODS

Study protocol and participants

We recruited study participants with glucose intolerance who did not take any hypoglycaemic agents or cholesterol-lowering agents from outpatients who visited the Department of Internal Medicine, National Center for Global Health and Medicine Kohnodai Hospital, between August 2012 and December 2013 (inclusion criteria). Briefly, we determined the existence of glucose intolerance in our outpatients and also diagnosed participants as having type 2 diabetes, IFG and IGT by performing the 75 g oral glucose tolerance test (OGTT) and the measurement of glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), casual plasma glucose and 2 h values in the OGTT. The participants were diagnosed as having type 2 diabetes according to diagnostic criteria set to serum levels of HbA1c ≥6.5%, FPG ≥126 mg/dL, casual plasma glucose ≥200 mg/dL and 2 h values in the OGTT ≥200 mg/dL. The participants were defined as having IFG and IGT according to FPG levels 110 mg/dL to 125 mg/dL, or 2 h values in the OGTT of 140 mg/dL to 199 mg/dL. To understand the effects of daily physical activity such as non-exercise activity thermogenesis (NEAT) on BNP and metabolic parameters, participants who were engaged in sports-like exercise and resistance training were excluded (exclusion criteria). Participants with heart failure and renal impairment were also excluded (exclusion criteria).

Anthropometric and physiological measurements

Height and weight were measured using a rigid stadiometer and scales (DP-7100PW, Yamato Co, Ltd, Hyogo, Japan). Waist circumference around the navel was measured with a metal anthropometric tape while participants were standing and breathing out. BMI was calculated as the body weight in kilograms divided by the height in metres squared. Blood pressure was measured with participants in a seated position using an automatic sphygmomanometer (HEM-762, Omron Co, Ltd, Kyoto, Japan).

Physical activity measurement

Daily physical activity was measured using a triaxial accelerometer (Active Style Pro HJA-350IT, Omron Co, Ltd, Kyoto, Japan), 74×46×34 mm and weighing 60 g including batteries. The study's participants wore the accelerometer on the left side of the waist. Anteroposterior, mediolateral and vertical acceleration measurements were obtained during each physical activity at a rate of 32 Hz to 12-bit accuracy. Each of three signals from the triaxial accelerometer was passed through a high-pass filter with a cut-off frequency of 0.7 Hz to remove the gravitational acceleration component. The ratios of unfiltered to filtered total acceleration (TAU/TAF) and filtered vertical and horizontal acceleration (VAF/HAF) were calculated to determine the cut-off value for the classification of locomotive activities and non-locomotive activities such as household and occupational activities, which resulted in an almost 100% accurate demarcation for the daily 11 different activities. Furthermore, metabolic equivalent values (METs) determined by this triaxial accelerometer have been reported to be closely correlated with METs calculated by using energy expenditure (EE) measured by indirect calorimetry. The study's participants wore the accelerometer on the left side of the waist for 7 consecutive days, and physical activities were recorded. They were requested to wear the accelerometer except under special circumstances such as sleeping, bathing and during aquatic activities. Activity data were stored on a minute-by-minute basis and were downloaded to a personal computer before analysis. We excluded days on which the participants did not wear the accelerometer for more than 8 h from the data for analysis.

Basal metabolic rate (BMR) was estimated from a multiple regression equation including age, sex, height and ideal body weight (IBW) as variables; the equation was as follows: BMR (kcal/day)=((0.128×h+0.481×IBW (kg) +0.0254×height (cm)—0.0138×age (year) —0.547×sex coefficient (man: 1, woman: 2))×293). Total energy expenditure (TEE) was calculated by a manufactured regression equation using METs assessed by the triaxial accelerometer. PAL was calculated by the following equation: PAL=TEE/BMR.

Blood examination, BNP measurements

After a 12 h overnight fast, blood samples were taken from the antecubital vein and collected into tubes. We measured FPG, HbA1c and serum insulin. FPG was measured using an enzymatic method (Wako Pure Chemical Industries, Osaka, Japan). Serum insulin and HbA1c were measured by automated ELISAs (TOSOH, Tokyo, Japan).
Japan). We used homeostasis model assessment-estimated insulin resistance (HOMA-IR) as the marker for insulin resistance.\textsuperscript{21} Plasma BNP (BNP 1-32) levels were measured using a specific immunoradiometric assay for human BNP (ARCHITECT BNP-JP, ABBOTT JAPAN Co, Ltd, Tokyo, Japan).\textsuperscript{22} Imprecision studies yielded within-run CVs of 1.1 to 5.1% and total CVs of 2.3 to 5.3% using human plasma based multiconstituent controls at concentrations of 92, 500 and 3500 ng/L.\textsuperscript{22}

Statistical analysis

Data were expressed as the mean±SD. Correlations among BNP, age, BMI, waist circumference, blood pressure, FPG, HbA1c, serum insulin levels, HOMA-IR and PAL were assessed by using Spearman’s rank correlation coefficient. Multiple regression analysis was performed to test the independent correlation of PAL with plasma BNP levels. We divided participants into the high-BNP group (≥8.0 pg/mL) and the low-BNP group (<8.0 pg/mL) by the median values of BNP. Differences in serum insulin levels, HOMA-IR and PAL between the high-BNP group and the low-BNP group were analysed by the Mann-Whitney U test. The statistical analyses were performed by using SPSS V.19 (IBM Co, Ltd, Chicago, USA). A \( p \) Value <0.05 was considered to be statistically significant.

RESULTS

We recruited 60 participants (28 men and 32 women) by the inclusion and exclusion criteria for participation in this study. Table 1 presents the clinical characteristics of studied participants. Thirty-one participants were diagnosed as having type 2 diabetes, 14 participants of studied participants. Thirty-one participants were diagnosed as having type 2 diabetes, 14 participants of studied participants. Thirty-one participants were diagnosed as having type 2 diabetes, 14 participants of studied participants. Thirty-one participants were diagnosed as having type 2 diabetes, 14 participants of studied participants. Thirty-one participants were diagnosed as having type 2 diabetes, 14 participants of studied participants. Thirty-one participants were diagnosed as having type 2 diabetes, 14 participants of studied participants. Thirty-one participants were diagnosed as having type 2 diabetes, 14 participants of studied participants. Thirty-one participants were diagnosed as having type 2 diabetes, 14 participants of studied participants.

| Table 1 Clinical and biochemical characteristics of participants |
|-----------------|--------------------|
| N               | 60                 |
| Age (years)     | 54.7±12.2          |
| Height (cm)     | 161.3±8.9          |
| Weight (kg)     | 69.2±16.1          |
| BMI (kg/m\(^2\))| 26.5±5.1           |
| Waist circumference (cm) | 92.4±13.1 |
| Systolic blood pressure (mm Hg) | 128.8±17.6 |
| Diastolic blood pressure (mm Hg) | 80.5±12.5 |
| Fasting plasma glucose (mg/dL) | 122.9±25.6 |
| HbA1c (%)       | 6.7±1.1            |
| BNP (pg/mL)     | 14.0±14.6          |
| Serum insulin (μU/mL) | 9.6±6.9 |
| HOMA-IR         | 3.02±2.62          |

Data are expressed as the mean±SD. BMI, body mass index; BNP, B-type natriuretic peptide; HbA1c, glycated haemoglobin; HOMA-IR, homeostasis model assessment-estimated insulin resistance.
highest plasma BNP quartile was also significantly lower than in the lowest plasma BNP quartile.

The mean±SD of plasma BNP levels in patients with type 2 diabetes (13 men and 18 women), IFG (5 men and 9 women) and IGT (10 men and 5 women) were 14.3±13.5 pg/mL, 12.9±17.2 pg/mL and 14.5±15.1 pg/mL, respectively. The mean±SD of PAL in patients with type 2 diabetes, IFG and IGT were 1.66±0.22, 1.65±0.15 and 1.66±0.20, respectively. There were no significant differences in plasma BNP levels and PAL among patients with type 2 diabetes, IFG and IGT.

**DISCUSSION**

Recent cross-sectional studies reported that plasma BNP or NT-proBNP levels were inversely associated with visceral fat, BMI, waist circumference and serum insulin levels. However, the effect of daily physical activity on plasma BNP levels remains unknown.

Previous cross-sectional studies have not ever been performed by using individuals with glucose intolerance as our study participants. In the present study, we examined the correlation of daily physical activity, measured objectively by a triaxial accelerometer with plasma BNP levels, in patients with prediabetes and early untreated type 2 diabetes.

This study demonstrates a significant and positive association between daily physical activity and plasma BNP levels, and also an inverse association of plasma BNP levels with BMI, waist circumference, serum insulin levels and HOMA-IR. Previous studies reported that exercise such as bicycle and hand-grip exercise acutely increase plasma BNP levels with exercise intensity in healthy individuals. However, the effect of daily physical activity on plasma BNP levels remains unknown. It is noteworthy that we could observe a significant effect of low-intensity daily physical activity, including walking, dining and washing clothes, defined as NEAT, on plasma BNP levels. Chainani-Wu et al previously conducted a nested prospective cohort study of a lifestyle intervention to understand the effects of lifestyle on BNP. They observed that the change in BNP for 3 months was significantly associated with the change in exercise score, even after controlling for the percentage of change in BMI, which agreed with a significant and positive correlation between PAL and plasma BNP levels after adjustment by age and BMI in our study. At 3 months in their study, they found an inverse association of the change in BNP with the changes in BMI and insulin, suggesting a significant association between BNP and insulin resistance.

An inverse association between natriuretic peptide and obesity and/or insulin resistance has been established. However, controversy exists as to this association. Lower natriuretic peptide levels in obese individuals has been reported to be due to increased clearance by the natriuretic peptide receptors (NPR)-C abundantly expressed in adipose tissue, and also due to decreased natriuretic peptide release from the heart. BNP binds to NPR on adipose tissue and stimulates lipolysis, regulates adipose tissue by activation

**Table 2** Correlations of plasma BNP levels to clinical and metabolic parameters

<table>
<thead>
<tr>
<th>Correlation coefficient</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>0.441</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>-0.256</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>-0.279</td>
</tr>
<tr>
<td>Systolic blood pressure</td>
<td>0.175</td>
</tr>
<tr>
<td>Diastolic blood pressure</td>
<td>m</td>
</tr>
<tr>
<td>Fasting plasma glucose</td>
<td>-0.237</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>0.050</td>
</tr>
<tr>
<td>Serum insulin (μU/mL)</td>
<td>-0.350</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>-0.363</td>
</tr>
</tbody>
</table>

A statistical analysis was performed by Spearman’s rank correlation coefficient.

BMI, body mass index; BNP, B-type natriuretic peptide; HbA1c, glycated haemoglobin; HOMA-IR, homeostasis model assessment-estimated insulin resistance.

**Figure 2** Serum insulin levels (A) and the homeostatic model assessment-estimated insulin resistance (HOMA-IR) (B) in the high-BNP group (n=30) and the low-BNP group (n=30). Data are mean values±SD. We divided participants into the high-BNP group (≥8.0 pg/mL) and the low-BNP group (<8.0 pg/mL) by the median values of BNP. Differences in serum insulin levels and HOMA-IR between the high-BNP group and the low-BNP group were analysed by the Mann-Whitney U test.

of proliferator-activated receptor γ (PPARγ) gene expression and increases adiponectin secretion, which improves insulin resistance.

Evidences for the association of glucose intolerance with BNP are very limited. A previous study reported that diabetes was significantly associated with low plasma BNP levels (adjusted OR 1.51 (1.00 to 2.27) for men; adjusted OR 1.95 (1.26 to 3.02) for women). However, the underlying mechanisms for low BNP levels in patients with impaired glucose metabolism remain unknown. In this study, PAL was positively correlated with plasma BNP levels, which were inversely correlated with the marker for insulin resistance. Furthermore, serum insulin levels and HOMA-IR were significantly lower in the high-BNP group as compared with those in the low-BNP group. BMI and waist circumference were also correlated with plasma BNP levels. Increased PAL may be associated with a reduction of BMI and waist circumference, which improves insulin resistance and induces elevation of plasma BNP, due to the decreased clearance by NPR-C abundantly expressed in adipose tissue. Otherwise, increased plasma BNP may ameliorate insulin resistance through various mechanisms, such as reduced oxidative stress, decreased systemic inflammation, stimulated lipolysis, activation of PPARγ gene expression and increased adiponectin secretion.

Recently, increased plasma BNP levels and/or biological activity could also improve insulin resistance by increasing mitochondrial fat oxidative capacity in white and brown fat, as well as in skeletal muscle. However, the cardiac ejection fraction is also inversely related to plasma BNP levels but is not beneficial and plasma BNP levels are reported to increase lipolysis and to be positively associated with insulin resistance. The relationships among PAL, BNP and insulin resistance in impaired glucose metabolism remain largely unknown. We should perform further studies, preferably using a greater number of patients with glucose intolerance.

There are several limitations that need to be considered when interpreting the results of this study. This is a cross-sectional study, which limits inferences of causality and its direction. Although we controlled for some confounding factors (age, sex, BMI, engagement in sports-like exercise or resistance training and medication), other factors such as genetic variation were not taken into account. Furthermore, we studied only patients with IFG, IGT and type 2 diabetes, and therefore our conclusions cannot apply to healthy populations. A heterogeneous group of individuals with IFG, IGT and type 2 diabetes was examined. We could not mention that the associations between BNP and physical activity or insulin resistance were the same in the three groups. We will study these associations by using a great number of patients with each type of glucose intolerance in the future. The triaxial accelerometer is an extensively validated device for evaluating physical activity under free living conditions, however, Leenders et al indicated that the predictive equations based on the relationship between acceleration and energy expenditure (EE) during locomotive movements led to an underestimation and overestimation of TEE. It is possible that EE and PAL assessed by a triaxial accelerometer differ from the true amounts of EE and PAL.

In conclusion, we found a significant and positive association between PAL and plasma BNP levels in patients with prediabetes and early untreated type 2 diabetes. Plasma BNP levels were inversely associated with insulin resistance. Our findings propose the possibility that BNP could be increased by daily physical activity and plasma BNP is beneficially associated with insulin resistance.

Author affiliations
1Department of Internal Medicine, National Center for Global Health and Medicine Kohnodai Hospital, Chiba, Japan
2Division of Complementary Medicine, First Department of General Medicine, Saitama Medical Center, Jichi Medical University School of Medicine, Saitama, Japan
3Department of Diabetes Research, Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, Japan
4Department of Human Health and Design, Faculty of Human Life and Environmental Sciences, Showa Women’s University, Tokyo, Japan
Contributors HH, HY and OE conceived and designed the study. HH and MN performed the study. HH, HY and MK analysed the data, interpreted the results and wrote the manuscript. HH and HY also discussed the analyses, interpretation and presentation and participated in the drafting of the manuscript.

Funding This study was supported by a grant from the National Center for Global Health and Medicine (25-203).

Competing interests None.

Patient consent Obtained.

Ethics approval The study was approved by the Medical Ethics Committee of the National Center for Global Health and Medicine (reference number NCGM-G-001212).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Funding

HH, HY and OE conceived and designed the study. HH and MN performed the study. HH, HY and MK analysed the data, interpreted the results and wrote the manuscript. HH and HY also discussed the analyses, interpretation and presentation and participated in the drafting of the manuscript.

Competing interests None.

Patient consent Obtained.

Ethics approval The study was approved by the Medical Ethics Committee of the National Center for Global Health and Medicine (reference number NCGM-G-001212).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES


